Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring pancreatic cancer, G17DT, gemcitabine
Eligibility Criteria
Inclusion criteria: Clinical diagnosis of pancreatic adenocarcinoma and unsuitable for pancreatic tumor resection Life expectancy of at least 3 months Functional status by Karnofsky Index of at least 70 Exclusion criteria: Prior treatment with chemotherapy, radiotherapy, or anti-cancer immunotherapy Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease Immunodeficiency Bone marrow transplant within past year Brain metastasis
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
B
A
Placebo (immunogen vehicle) combined with gemcitabine.
500 µg G17DT immunogen combined with gemcitabine.